FundedIQ
Biotechnology

ACELYRIN: Funding, Investors & Team (Sep 2026)

ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.

acelyrin.com LinkedIn Los Angeles, United States 11-50 employees
Total raised
$300M
Rounds
1
Latest
Series C
Sep 2022

ACELYRIN has raised $300M across 1 funding round on record, the most recent a Series C of $300M announced in Sep 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

ACELYRIN Company Profile and Key Stats

Total funding raised
$300M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series C
$300M in Sep 2022
Employees
11-50
reported band
Headquarters
Los Angeles, United States

Latest funding round on record: Sep 2022.

ACELYRIN Funding Rounds

Date
Round
Amount
Series C
$300M

ACELYRIN Founders and Leadership Team

Name
Role
Contact
Robert Carey
Founder
Locked

Contact details for the ACELYRIN team: 1 of 1 has an email address on file.

Start 14-day free trial →

ACELYRIN Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M
1,822
$58M

ACELYRIN's latest round of $300M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like ACELYRIN in Biotechnology and Los Angeles

Companies Similar to ACELYRIN

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

ACELYRIN Funding FAQs

What does ACELYRIN do?

ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.

How much funding has ACELYRIN raised?

ACELYRIN has raised $300M across 1 round on record. The most recent is a Series C of $300M announced in Sep 2022.

When did ACELYRIN last raise funding?

ACELYRIN's most recent funding round on record is a Series C of $300M, announced in Sep 2022.

Who founded ACELYRIN?

FundedIQ lists Robert Carey (Founder) at ACELYRIN.

Where is ACELYRIN headquartered?

ACELYRIN is based in Los Angeles, California, United States.

How many employees does ACELYRIN have?

ACELYRIN is in the 11-50 employee band.

How does ACELYRIN's funding compare to other Biotechnology startups?

ACELYRIN's latest round of $300M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's ACELYRIN Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ACELYRIN is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.